Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • DAIICHI SANKYO S/ADR News

    32,20 $ +4,34% +1,34 $
    In : 30,046 € | 26.04.24 21:52:00 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    ISIN: US23381D1028
    US-Symbol: DSNKY
    Typ: Aktie

    DAIICHI SANKYO S/ADR News

    21.12.22 - PR Newswire
    Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
    Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire
    20.08.20 - PR Newswire
    ETNA-AF-Europe Registry Data on LIXIANA®▼(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation
    ETNA-​AF-Europe Registry Data on LIXIANA®▼(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with ...
    18.12.19 - PR Newswire
    Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
    Large Real-​World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities PR Newswire
    04.09.19 - PR Newswire
    Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation
    Daiichi Sankyo Presents Positive Results of the ENTRUST-​AF PCI Study of LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation PR Newswire
    19.03.19 - PR Newswire
    CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
    CLEAR Wisdom Demonstrated First-​in-class, Oral, Once-​daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-​Cholesterol and Reduced hsCRP PR Newswire
    18.03.19 - PR Newswire
    Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
    Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-​daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing ...
    07.01.19 - PR Newswire
    Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
    Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
    19.11.18 - PR Newswire
    Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
    Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference PR Newswire
    08.11.18 - PR Newswire
    Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018
    Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018 Company invites individual and institutional investors, as well as ...
    06.11.18 - PR Newswire
    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018
    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018 PR Newswire
    06.08.18 - PR Newswire
    New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®▼ (edoxaban)
    New Analysis Identifies Patient Populations With Cancer-​associated VTE Who Could Benefit From Treatment With Oral, Once-​daily LIXIANA®▼ (edoxaban) PR Newswire
    06.08.18 - PR Newswire
    New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®▼ (edoxaban)
    New Analysis Identifies Patient Populations With Cancer-​associated VTE Who Could Benefit From Treatment With Oral, Once-​daily LIXIANA®▼ (edoxaban) PR Newswire
    18.05.18 - PR Newswire
    LIXIANA® ▼ (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
    LIXIANA® ▼ (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-​analysis Presented at the European Stroke ...
    20.11.17 - PR Newswire
    Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
    Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference PR Newswire
    13.11.17 - PR Newswire
    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 15th and 16th, 2017
    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 15th and 16th, 2017 PR Newswire
    13.11.17 - PR Newswire
    Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15th, 2017
    Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15th, 2017 PR Newswire
    31.08.17 - PR Newswire
    Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
    Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108 PR ...
    29.08.17 - PR Newswire
    New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
    New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire
    29.08.17 - PR Newswire
    New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
    New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire
    29.08.17 - PR Newswire
    New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
    New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »